The prescription drug middlemen have been an increasingly prominent target of finger-pointing.
Driving the news:
There are no specific allegations of wrongdoing, but practices to be scrutinized include familiar points of contention like how PBMs negotiate drug prices on behalf of health plans and decide which medicines get preferential treatment, according to an analyst note from Evercore ISI.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: